A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

NCT07197697 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Iparomlimab and Tuvonralimab Injection (QL1706) combined chemotherapy

Sponsor

Anhui Provincial Cancer Hospital